Everolimus treatment in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer and a predictive model for its efficacy: a multicenter real-world study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.A new predictive model identifies risk factors for everolimus efficacy in advanced breast cancer (ABC). This tool helps predict survival outcomes for hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) ABC patients.
Area Of Science
- Oncology
- Pharmacology
- Clinical Medicine
Background
- Everolimus is a key treatment for hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC).
- Limited predictors exist for everolimus efficacy, and some patients develop drug resistance.
Purpose Of The Study
- To evaluate everolimus efficacy across different treatment lines in HR+/HER2- ABC.
- To identify clinicopathological markers for predicting everolimus efficacy in this patient population.
Main Methods
- Retrospective, multicenter study involving over 2000 patients treated with everolimus between 2014-2022 in China.
- Development of training and two validation cohorts.
- Analysis of clinicopathological characteristics and survival outcomes, including progression-free survival (PFS).
Main Results
- Median PFS for everolimus was 5.6 months (Objective Response Rate: 25.1%, Clinical Benefit Rate: 54.4%).
- PFS significantly decreased with later treatment lines (1L: 13.5 months, 2L: 6.1 months, 3L: 4.1 months).
- Independent risk factors for poor PFS included post-first-line everolimus treatment, Ki67 >40%, >2 metastatic sites at first recurrence, and adjuvant chemotherapy.
- A predictive model incorporating these four factors demonstrated strong predictive power (AUCs 0.94-0.96) and was validated internally and externally.
Conclusions
- A robust predictive model was developed to estimate survival outcomes for everolimus in HR+/HER2- ABC patients.
- This model can aid in clinical decision-making and management strategies for everolimus therapy in Chinese patients.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...